Levosimendan was first approved for clinical use in 2000, when authorization was granted
by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely …

Levosimendan, a calcium sensitizer and potassium channel-opener, is widely appreciated
by many specialist heart failure practitioners for its effects on systemic and pulmonary …

Background Cardiogenic shock (CS) and low cardiac output syndrome (LCOS) are
potentially life‐threatening complications of acute myocardial infarction (AMI), heart failure …

Introduction: In the 20 years since its introduction to the palette of intravenous hemodynamic
therapies, the inodilator levosimendan has established itself as a valuable asset for the …

SEPARATION from cardiopulmonary bypass (CPB) after cardiac surgery is a progressive
transition from full mechanical circulatory and respiratory support to spontaneous …

Levosimendan is a distinctive inodilator combing calcium sensitization, phosphodiesterase
inhibition and vasodilating properties through the opening of adenosine triphosphate …

Background Few data are available on the impact of levosimendan in refractory cardiogenic
shock patients undergoing peripheral venoarterial extracorporeal membrane oxygenation …

Background The administration of levosimendan prophylactically to patients undergoing
cardiac surgery remains a controversial practice, and few studies have specifically assessed …

Levosimendan is an inodilator that promotes cardiac contractility primarily through calcium
sensitization of cardiac troponin C and vasodilatation via opening of adenosine triphosphate …

Cardiac involvement during sepsis frequently occurs. A series of molecules induces a set of
changes at the cellular level that result in the malfunction of the myocardium. The …